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Spinal muscular atrophy (SMA) is a severe neuromuscular disease affecting children, due to mutation/deletion
of survival motor neuron 1 (SMN1) gene. The lack of functional protein SMN determines motor neuron (MN)
degeneration and skeletal muscle atrophy, leading to premature death due to respiratory failure. Nowadays, the
Food and Drug Administration approved the administration of three drugs, aiming at increasing the SMN pro-
duction: although assuring noteworthy results, all these therapies show some non-negligible limitations, mak-
ing essential the identification of alternative/synergistic therapeutic strategies. To offer a valuable in vitro
experimental model for easily performing preliminary screenings of alternative promising treatments, we opti-
mized an organotypic spinal cord culture (derived from murine spinal cord slices), which well recapitulates the
pathogenetic features of SMA. Then, to validate the model, we tested the effects of human mesenchymal stem
cells (hMSCs) or murine C2C12 cells (a mouse skeletal myoblast cell line) conditioned media: 1/3 of condi-
tioned medium (obtained from either hMSCs or C2C12 cells) was added to the conventional medium of the
organotypic culture and maintained for 7 days. Then the slices were fixed and immunoreacted to evaluate the
MN survival. In particular we observed that the C2C12 and hMSCs conditioned media positively influenced
the MN soma size and the axonal length respectively, without modulating the glial activation. These data sug-
gest that trophic factors released by MSCs or muscular cells can exert beneficial effects, by acting on different
targets, and confirm the reliability of the model. Overall, we propose the organotypic spinal cord culture as an
excellent tool to preliminarily screen molecules and drugs before moving to in vivo models, in this way partly
reducing the use of animals and the costs.
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Introduction
Spinal muscular atrophy (SMA) is a progressive neurodegen-
erative disorder and one of the main causes of infantile mortality.
It is characterized by the degeneration and loss of lower motor neu-
rons (MNs), determining a progressive muscle atrophy, respiratory
failure and, in most severe cases, premature death.1 SMA is due to
the homozygous deletion or mutation of the Survival Motor
Neuron 1 (SMN1) gene, resulting in the lack of the full-length
SMN (FL-SMN) protein. Humans also carry an almost identical
gene called SMN2 which in the 90% of cases undergoes an alter-
native splicing, mainly producing a trunked (lacking exon 7,
SMNΔ7) and not-functional protein. The SMN2 copy number
inversely correlates with the disease severity.2
Since the genetic causes of SMA are well known, the current
available treatments (Spinraza, Zolgensma and Evrysdi) consist in
SMN-dependent approaches: however, albeit effective, they pres-
ent several limitations, such as high costs, still unknown long-term
effects, uncomfortable administration route (Spinraza) and some
side effects;3,4 moreover they disregard SMN-independent targets,
although additional cellular and molecular mechanisms have been
demonstrated contributing to MN death (in particular autophagy
and apoptosis dysregulation)5,6 and muscular atrophy/innervation
(neurofilament accumulation, denervation and neuromuscular
junction immaturity).7 Therefore, the identification of
alternative/synergistic therapeutic strategies is still a hot topic in
the SMA field.
Most clinical trials based on experimental results fail to obtain
significant effects on human patients, therefore, it is necessary to
improve the preclinical model reliability, possibly replacing/reduc-
ing animal studies with valid in vitro models. A good compromise
between 2D cell cultures and experimental animal models is repre-
sented by 3D cultures, as organotypic cell cultures. This method
allows easy and repeated manipulation while maintaining intact
morphology and local synaptic connections in vitro (reminiscent of
the in vivo situation). Indeed, organotypic slice cultures are very
useful to study the tissue cytoarchitecture, thanks to long-term sur-
vival, the preservation of regional differentiation, neuroanatomic
organization and cell-to-cell interaction.8 Moreover, compared to
animal models, organotypic cultures require fewer animals, allow
real time monitoring and are less expensive.9
In this scenario, to easily perform a preliminary screening of
promising treatments,10 we developed a 3D organotypic spinal
cord culture (by adapting the most used method, i.e. the ‘mem-
brane technique’ or interface method11), which well recapitulated
the pathogenetic features of SMA: in particular, to assess the neu-
rodegeneration, we evaluated the MN soma size and axonal length,
two parameters previously reported as altered in SMA.12,13 To ver-
ify the reliability of the model, we tested on SMA slices the
paracrine effects of human mesenchymal stem cells (hMSCs) or
murine C2C12 cells (a mouse skeletal myoblast cell line). The
secretome of these cells (especially MSCs) has been extensively
studied and proposed as therapeutic tool for many neurodegenera-
tive and traumatic pathologies: indeed, the broad range of secreted
factors can exert beneficial effects as inhibiting cell death and
oxidative stress, enhancing immunomodulation and angiogenesis,
stimulating neurogenesis, supporting regeneration, therefore coun-
teracting many SMN-independent altered pathways in SMA.14-19
This work represents a proof-of-concept study, demonstrating
the possibility to use the 3D organotypic spinal cord culture as an
effective therapeutic screening tool; moreover, even if the results
here presented refer to SMA, this model could be suitable for all
the other MN and neuromuscular diseases.
Materials and Methods
Experimental model
The original breeding pairs of SMA mice were purchased from
Jackson Laboratory (stock number 005025; Jackson Lab, Bar
Harbor, ME, USA). To maintain the colony, carrier mice (SMN2+/+;
SMNΔ7+/+; Smn+/-) were interbred and the offspring was genotyped
by PCR assays as previously described:20 briefly, animals were
genotyped for the presence of the two human transgenes (SMN2
and SMNΔ7) and the three possible genotype variants of the
mouse Smn locus (Smn+/+, Smn+/− and Smn−/−). WT (Smn+/+) and
SMA (Smn−/−) animals were used to perform organotypic cell cul-
tures.
Animals had free access to food and water. All experimental
procedures on live animals were performed according with nation-
al (DL n. 116, G.U., Supp. 40, February 18, 1992; permit number
17/2010-B, June 30, 2010) and European Community Council
guidelines (Council Directive 86/609/EEC). Additionally, an ad
hoc Ethical Committee of the University of Turin specifically
approved this study. Particular care was taken to minimize the
number of animals, their discomfort and pain.
Organotypic cell cultures
At postnatal day 8 [P8, identified from pilot experiments (here
not shown) as the most suitable time point to assure good cell sur-
vival and slice morphology], SMA (n=15) and WT animals (n=16)
were decapitated and the T13-L5 spinal cord segments were rapid-
ly dissected. After removal, the samples were cut into 350 µm-
thick sections (about 10 per dissected segment) with a mechanical
tissue chopper (McIlwain) and the slices were immediately trans-
ferred in ice-cold 6% glucose saline solution. Organotypic cultures
were prepared according to the standard membrane interface
method.11 The isolated slices were transferred onto a porous
translucent membrane (Millicell®-CM:PICM03050, Millipore,
Billerica, MA, USA) and placed in a petri dish with 1 mL of medi-
um. i.e., a mixture of 50% MEM (Invitrogen-Gibco, Waltham,
MA, USA) with 25 mM HEPES (0.625 ml in 25 mL; Sigma-
Aldrich, St. Louis, MO, USA), 25% horse serum, 25% HBSS with
glucose 25.76 mg/mL 1% glutamine, 1% penicillin/streptomycin.21
The slices were maintained in the interface between culture medi-
um, in a humidified atmosphere of 95% air with 5% CO2 at 37°C.
The medium was changed at day 2 and 5 after seeding, and the cul-
ture was maintained for 7 days. During the whole period in culture,
the slices were observed and monitored with a Leica 0 550FW
inverted phase contrast microscope, equipped with an Euromex
digital camera.
To evaluate the efficiency of protocol and exclude artifacts,
immediately after the tissue chopper cutting some organotypic
slices were fixed with 4% paraformaldehyde (PFA) in 0.1M phos-
phate buffered saline (PBS) for 4 h at 4°C, washed with PBS and
then immunoreacted as described in the following paragraph.  
Cell cultures and collection of conditioned media
C2C12 cells (mouse skeletal myoblast cell line) and human
mesenchymal stem cells (hMSCs) were prepared and expanded as
follows (respectively according to22,23). C2C12 cells from ATCC
[ATCC-LGC Standards S.r.l., Sesto San Giovanni (MI), Italy] were
cultured in DMEM high glucose (Sigma-Aldrich) with 10% fetal
bovine serum (FBS; Sigma-Aldrich), containing 2 mM L-gluta-
mine, 100 U/mL penicillin and 100 μg/mL streptomycin
(Invitrogen-Gibco). Cells were maintained in a humidified atmos-
phere of 95% air with 5% CO2 at 37°C. In order to allow C2C12
myoblasts to differentiate into myotubes, the serum concentration
was reduced to 3% (myotube formation took about 5 days). On day
[page 59][European Journal of Histochemistry 2021; 65(s1):3294]
2021_s 1 Article.qxp_Hrev_master  04/11/21  15:39  Pagina 59
                             Article
5 post-differentiation, the surnatant was collected.
Concerning hMSCs, bone marrow was aspirated from the iliac
crest of healthy donors after informed consensus in accordance
with the Declaration of Helsinki and the City of Health & Science
of Turin - Ordine Mauriziano Hospital Ethics Committee. Cells
were plated at 8×105 cells/cm2 in T flasks, and cultivated in Eagle’s
alpha minimum essential medium (a-MEM; Cambrex Bioscience,
East Rutherford, NJ, USA), containing 10% FBS, 2 mM L-gluta-
mine (Invitrogen-Gibco), 100 U⁄mL penicillin and 100 μg⁄mL
streptomycin (Invitrogen-Gibco). Cells were maintained in a
humidified atmosphere of 95% air with 5% CO2 at 37°C. After 3
days free floating cells were removed and replaced with fresh cul-
ture medium. The cells were analyzed for their viability and for
their immunophenotype by flow cytometry (data not shown), as
reported by Mareschi et al.23 At 4-5th passage, when at about 80%
confluence, we collected the surnatant after approximately 24-48 h
after refreshing medium.
After collection, both conditioned media were centrifuged at
2000 RPM for 5 min, to remove detached cells and stored at −80°C
until further use.
Treatment with conditioned media
At day 7 in vitro (7 DIV) in standard conditions, SMA (n=9)
and WT (n=8) organotypic cultures underwent a treatment with
conditioned media for additional 7 days (replaced once during the
week), in order to study their potential neuroprotective effects and
to validate the model. As controls, other organotypic cultures were
maintained in standard medium (SMA untreated n=6; WT untreat-
ed n=8).
In detail, the WT and SMA organotypic cultures were incubat-
ed with 2/3 of conventional medium and 1/3 of conditioned medi-
um obtained by either a culture of C2C12 cells or a culture of
hMSCs. Accordingly, the different experimental conditions will be
referred as WT hMSCs (n=4), WT C2C12 (n=4), SMA hMSCs
(n=4) and SMA C2C12 (n=5), depending on the genotype and the
treatment. 
Altogether after 14 DIV, both treated and control organotypic
SMA and WT slices were fixed with 4% PFA in 0.1M PBS for 4 h
at 4°C, and then extensively washed with PBS. 
Immunofluorescence reactions
For the immunofluorescence (IF) reactions, SMA (n=23) and
WT (n=24) sections were washed three times (5 min each) with
PBS. To allow cell permeabilization, the samples were eventually
incubated for 20 min with PBS-Triton 0.3% at room temperature
(RT) and then washed with PBS. After the incubation for 30 min in
a blocking solution containing 10% Normal Donkey Serum (NDS)
and PBS-Triton 0.3%, the samples were incubated with the follow-
ing primary antibodies, at 4°C for 48 h: monoclonal anti-micro-
tubule-associated protein 2 (MAP2) (anti-mouse; 1:200;
Chemicon®, Sigma-Aldrich); polyclonal anti-glial fibrillary acidic
protein (GFAP) (anti-rabbit; 1:500; Dako Cytomation, Glostrup,
Denmark); monoclonal anti-neurofilament SMI32 (anti-mouse,
1:1000; Covance, Princeton, NJ, USA); monoclonal anti-Ki67
(anti-mouse, 1:400; Novocastra Laboratories, Ltd., Newcastle
upon Tyne, UK); polyclonal anti-ionized calcium binding adaptor
molecule 1 (IBA1) (anti-rabbit, 1:500; Wako). Afterwards the sam-
ples were washed in PBS and incubated for 1  at RT with 1:200
anti-rabbit or anti-mouse cyanine 3-conjugated secondary antibod-
ies (Jackson ImmunoResearch Laboratories, West Grove, PA,
USA), as appropriate. Then the slices were incubated with 4’-6-
Diamidino-2-phenylindole (DAPI) 1:50 in PBS, for labelling the
cell nuclei. Finally, coverslips were mounted on the slices with a
drop of PBS-glycerol 1:1. 
Morphometric analyses
The slices were analyzed with a Nikon Eclipse 90i epifluores-
cence microscope and photographed by a Nikon DS-5Mc digital
camera. For checking double staining and making 3D reconstruc-
tions, some preparations were examined also with a Leica TCS
SP5 confocal laser scanning microscope.
For evaluating the effects of conditioned media, the analysis of
cell bodies and axons was performed with the Neurolucida soft-
ware (extension module AutoNeuron) and the associated data
analysis software NeuroExplorer (MicroBrightField): for the mor-
phometric analysis, only SMI32-positive neurons located in the
ventral horns and presenting a diameter not smaller than 10 µm
were considered alpha MNs (according to6,12) and were drawn and
measured (WT untreated n=32; WT hMSCs n=6; WT C2C12
n=15; SMA untreated n=19; SMA hMSCs n=5; SMA C2C12
n=18).
Statistical analysis
Data are shown as mean ± standard error of mean (SEM) and
inter-group differences were statistically compared: unpaired t-test
two tails was used for morphological analysis (MN soma size and
axonal length) between SMA and WT organotypic slices, while
one way ANOVA for comparing the treatment effects in WT or
SMA conditions. Differences were considered to be significant
when p≤0.05. Statistical analysis was performed using GraphPad
Prism 6.0 software (GraphPad Software, San Diego, CA, USA).
Results
The organotypic spinal cord culture model
We have optimized a protocol -starting from the Stoppini’s
interface method10- able to ensure excellent tissue preservation and
cell survival (in terms of well-preserved morphology, structure and
dorso-ventral orientation of the slices) during the whole observa-
tion period of the organotypic cultures, although a physiological
limited degradation of the slices was progressively observed at the
edges (starting from 4 DIV) (Figure 1A). During the whole obser-
vation period (14 days), the spinal cord slices appeared intact, with
the dorsal and ventral horns well recognizable. Pyknotic nuclei
(identifying dying cells) were not observed (data not shown).
Immediately after tissue chopper cutting, neither signs of alter-
ation nor astrogliosis (identified by GFAP immunolabeling) were
detected (Figure 1B), while it tended to appear during the follow-
ing days (Figure 1C), both in WT and SMA slices. Moreover,
SMI32-positive MNs were easily detectable, in good conditions
and correctly placed in the ventral horns both immediately after
cutting (Figure 1D) and until 14 DIV in WT animals (Figure 1E).
In absence of any treatments, at 14 DIV we measured the cell
body size and the axon length of the MNs by the Neurolucida soft-
ware (Figure 2): we observed significant differences in the soma
area between WT and SMA samples (WT 655.21 µm2 ± 53.33;
SMA 476.78 µm2 ± 50.65; unpaired t-test p≤0.05), and a trend in
the axonal length reduction (WT 564.08 µm ± 63.43; SMA 381.02
µm ± 56.14; unpaired t-test p>0.05). These analyses confirmed the
occurring atrophy and neurodegeneration affecting SMA MNs
compared to the WT ones, and demonstrated the reliability of the
organotypic culture as a valid model to study SMA hallmarks and
to preliminary test the treatment efficacy.
Organotypic culture treatment
After 7 DIV, the standard medium was replaced for WT (n=11)
and SMA (n=12) slices with hMSCs or C2C12 cell conditioned
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medium and maintained for additional 7 days, before PFA-fixa-
tion. Control slices were maintained in standard medium for the
whole observation period.
We first evaluated the effect of the conditioned media on WT
cells. MN soma areas were not influenced by any treatment (WT
untreated 655.21 µm2 ± 53.33; WT hMSCs 635.87 µm2 ± 146.32;
WT C2C12 652.85 µm2 ± 57.98; one way ANOVA p>0.05).
However, the axonal length was slightly increased by the presence
of C2C12 conditioned medium (WT untreated 564.08 µm ± 63.43;
WT hMSCs 439.22 µm ± 92.89; WT C2C12 660.12 µm ± 112.95;
one way ANOVA p>0.05), even if these differences were not sig-
nificantly different (Figure 3).
Concerning the SMA organotypic cultures, both treatments
induced an effect, although influencing different parameters. The
administration of C2C12 conditioned medium (Figure 4) signifi-
cantly affected the MN area (SMA untreated 476.78 µm2 ± 50.65;
SMA C2C12 659.58 µm2 ± 46.24; one way ANOVA p≤0.05), but
not the axonal length (SMA untreated 381.02 µm ± 56.14; SMA
C2C12 359.99 µm ± 38.82; one way ANOVA p>0.05). On the con-
trary, in presence of hMSCs conditioned medium (Figure 4), the
axonal length was significantly increased in SMA treated MNs
compared to untreated and C2C12 treated conditions (SMA
untreated 381.02 µm ± 56.14; SMA hMSCs 717.38 µm ± 228.05;
SMA C2C12 359.99 µm ± 38.82; one way ANOVA p≤0.05); as
regards the soma size, it was not affected by the hMSC secretome
(SMA untreated 476.78 µm2 ± 50.65; SMA hMSCs 433.67 µm2 ±
110.57; one way ANOVA p>0.05).
Moreover, independently from the genotype and the group, a
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Figure 1. A) The time lapse analysis shows the gradual modifica-
tions occurring to a representative organotypic spinal cord SMA
slices, during the 14 DIV: although a progressive thinning of the
section was evident (from 4 DIV), overall the slice morphology
appeared well preserved during the whole period of observation. B)
Immediately after the tissue chopper cutting, no signs of astrogliosis
(GFAP) were evident (here showed a SMA slice), whereas C) it
increased over time (as visible in this representative WT slice). D)
Concerning the cell preservation, at 1 DIV the WT MNs (SMI32-
positive cells) were in good conditions and showed numerous neu-
rites (well visible in the inset D’). E) At 14 DIV, the WT MN sur-
vival was still good: the cells were correctly located in the ventral
horns and several extensions were detectable (a detail is appreciable
in the inset E’). Scale bar: A-E) 500 µm; D’, E’) 250 µm.
Figure 2. Morphological analysis highlighted the soma atrophy
and axonal degeneration occurring in SMA MNs compared to
WT MNs (unpaired t-test *p≤0.05).
Figure 3. hMSCs and C2C12 conditioned media, administered to
WT organotypic slices, did not induce evident modification of
the MN soma area. A slight increase of MN axonal length was
observed in presence of C2C12 conditioned medium.
Figure 4. The administration of C2C12 conditioned medium sig-
nificantly increased the cell body area of SMA MNs, whereas the
hMSCs conditioned medium significantly affected the SMA MN
axonal length (one way ANOVA *p≤0.05).
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certain degree of astrocyte activation appeared during the days:
however, the treatment with either hMSC or C2C12 conditioned
media did not seem to modulate the astrogliosis, although these
observations were only qualitative (Figure 5A).
Finally, as previously stated, during the 14 DIV of observation
a physiological limited degradation of the slices is progressively
observed at the edges (involving the white matter), characterized
by a progressive centrifugal migration of the cells: indeed, during
the days, the slice borders tended to become progressively thinner,
and the cells appeared as arranged in a monolayer in proximity to
the white matter, seemingly moving away from the slice edges: this
progressive flattening has been already reported by other authors.24
In case of C2C12 conditioned treatment, it appeared slightly more
pronounced (Figure 5B). Among the involved cells, in particularly
we observed GFAP-positive and IBA1-positive cells (Figure 5
C,D). Rare MNs (SMI32-positive) were observed among the
migrating cells (data not shown).
In conclusion, these data suggest that the SMA spinal cord
organotypic culture is a reliable model and, as a validation, we
demonstrated that different treatments can effectively influence
different MN morphology-related features.
Discussion
The study aimed to develop a reliable 3D in vitro model of
SMA, using organotypic culture technique. This method allowed
maintaining the tissue slices alive until 14 DIV after their cutting,
preserving quite intact the in vivo cytoarchitecture and highly sim-
plifying the experimental conditions. This is a pivotal approach i)
to study pathogenetic mechanisms in a rather complex cellular
environment; ii) to preliminary screen and select hit compounds
and drugs, using a 3D model (composed by different cell types,
interacting each other); iii) to discard ineffective molecules before
going to in vivo experiments; and consequently iv) to highly
reduce the use of experimental animals and the therapeutic failure
of clinical trials.
The protocol employed is based on the Stoppini’s interface
method11, but has been optimized for this work. Stoppini’s tech-
nique was conceived in particular for brain organotypic cultures.
We placed the spinal cord slices at the air-medium interface on
millicell semiporous membranes, maintaining them stationary dur-
ing the entire culturing process: in this way, they received oxygen
from above and medium from below.25 With this procedure the
cells can potentially survive more than 2 months, maintaining their
metabolic and structural characteristics and allowing both electro-
physiological and morphological experiments.11 In our experimen-
tal design, we decided to stop the cultures after 14 DIV, according
to the average lifespan of the employed SMA model.
Organotypic cultures show evident advantages compared to
standard in vitro models. Indeed, they assure a complex 3D archi-
tecture and maintain local neuronal circuits, although the pathways
are largely disconnected and the axotomy can induce neuronal cell
death.10,26 However in our optimized protocol we did not detect
massive apoptosis. Moreover, the organotypic cultures can also
maintain the interactions between neurons and glial cells, allowing
to understand their crosstalk (largely involved in the pathogenesis
of several neurological diseases27). Finally, compared to other 3D
cell cultures (as organoids), organotypic cultures are better stan-
dardized, more homogenous and cheaper.28 Moreover, compared to
in vivo animal models, organotypic cultures require fewer animals,
allow real time monitoring and are less expensive.9
Here, we developed a 3D organotypic spinal cord culture,
which well recapitulates the pathogenetic features of SMA and can
be used to preliminary screen therapeutic molecules. Indeed, we
compared the morphology of SMA and WT MNs, and we observed
a significant reduction of cell body area and a remarkable (albeit
not significant) axonal length decrease in the SMA samples. These
data highlight the reliability of the model, since both the decrease
of MN soma size12 and the reduction in axon length13 have been
previously described in vivo in SMNΔ7 MNs. Therefore, these fea-
tures confirm the occurring SMA-related neurodegeneration.
However, as concerns the neuroinflammation, at 14 DIV we
observed a certain degree of astrogliosis both in WT and SMA
slices, suggesting that it was more due to a technical concern than
to the disease per se. 
As a proof-of-concept study, we tested the effect of paracrine
effects of hMSCs and C2C12 conditioned media. As known, the
secretome of MSCs consists in several bioactive molecules
(including neurotrophins, microRNAs, hormones, cytokines and
interleukins) with remarkable neuroprotective, anti-inflammatory,
immunoregulatory, angiogenic and trophic effects:29 indeed their
positive and supportive effects have been demonstrated in several
neurodegenerative and traumatic disease models.15,30,31 On the
other hand, the C2C12 cells are known to secrete the so-called
“myokines”, molecules able to influence metabolic regulation,
inflammatory processes, angiogenesis, and myogenesis.32
Therefore we evaluated their effect on WT and SMA organotypic
spinal cord cultures. In the WT we only observed a slight increase
(not statistically significant) in the MN axonal length triggered by
C2C12 conditioned medium, whereas the soma size did not vary in
any conditions. It is likely that for the WT slices (i.e., in healthy
conditions) the conditioned media supplement did not exert partic-
ular additive effects. Instead, in the SMA samples, we observed a
different effect induced by hMSCs and C2C12 cells, which respec-
tively determined an increase in the axonal length and in the cell
Figure 5. A) Neither treatment was able to modulate astrogliosis,
B) but C2C12 conditioned medium administration increased the
dispersion of cells from the slice edges (as demonstrated by the
numerous DAPI positive nuclei located over the edge of the
slice): C) among the migrating cells, we mainly observed
microglial (IBA1 positive) and D) astrocytes (GFAP positive).
DAPI was used to label the cell nuclei. Scale bar: A,B) 500 µm;
C-D) 50 µm.
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body area. These effects probably reflect the different mixture of
cell type secretome. Indeed, on one side, MSC paracrine activity
effectively prevented the axon length reduction due to SMN lack,33
supporting axonal elongation thanks to several factors and
miRNAs (as BDNF and miRNA-17-92 cluster) presented in the
MSC-exosomes.34-36 On the other side, the neurotrophic factors (as
FGF21, IGF1 and TGFb1) produced by C2C1232 and contained in
their conditioned medium have been able to counteract the MN
soma atrophy, a feature already observed in SMA mice and proba-
bly antecedent to the MN cell death.12 Moreover in presence of
C2C12 conditioned media, we observed a progressive centrifugal
migration of the spinal cord cells, possibly in the attempt to
arrange in a monolayer in search to a better access to nutrients
present in the C2C12-medium, compared to the multilayer dispo-
sition in the slice. Lastly, we cannot exclude that the presence of
FBS in the culture medium could partially affect the morphological
changes we observed37 as well as its eventual deprivation:38 how-
ever, the significant differences between the treated and untreated
samples confirm the prevailing and effective action of the condi-
tioned media. 
Finally, although it is well known the anti-inflammatory effect
exerted by these cells, we did not notice a reduction of astrocyte
activation in neither condition: however, as previously stated, a
certain degree of astrogliosis is always present at 14 DIV (also in
WT slices), therefore the conditioned media could be not sufficient
to counteract such phenomenon.
To conclude, it is evident that the 3D organotypic spinal cord
model proposed is valid and useful, since in presence of two dif-
ferent treatments we appreciated a number of varied effects. In par-
ticular we suggest the use of this model to unravel cell death mech-
anisms or cell-glia interactions, and to preliminary screen neuro-
protective molecules. In addition, it could be also possible to set-
up a co-culture (with organotypic spinal cord slices and muscular
cells), to study the neuron-muscle interplay and the innervation
mechanisms (known to be altered in SMA7), and test therapies to
support these phenomena.
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